Look back at pharma news in the week to June 14

16 June 2019

By Barbara Obstoj-Cardwell. Editor

Last week’s M&A news included Merck & Co’s proposed acquisition of spin-out Tilos Therapeutics to expand its immunotherapy portfolio, though the TGF-beta sector already looks quite busy. Also, Roche’s planned $4.8 billion acquisition of Spark Therapeutics hit another stumbling block with the US competition regulator. On the regulatory front, there was US Food and Drug Administration for Roche’s B-cell lymphoma drug Polivy. Additionally, Celgene revealed that filings for its multiple sclerosis candidate ozanimod have been accepted by the FDA and the European Medicines Agency.

Merck to buy private Tilos in deal worth up to $773 million

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK